Anti-Human/Mouse integrin β7 (Clone FIB21) – Purified in vivo GOLD™ Functional Grade

Anti-Human/Mouse integrin β7 (Clone FIB21) – Purified in vivo GOLD™ Functional Grade

Product No.: F118

[product_table name="All Top" skus="F1196"]

- -
- -
Clone
FIB21
Target
Integrin Beta 7
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
β7 Integrin, integrin β7, ITGB7
Isotype
Rat IgG2a
Applications
B
,
FC
,
in vivo

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Mouse
Host Species
Rat
Recommended Isotype Controls
Recommended Dilution Buffer
Immunogen
TK1 cells
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
< 1.0 EU/mg as determined by the LAL method
Purity
≥95% monomer by analytical SEC
>95% by SDS Page
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day 2-8°C
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
Anti-Human/Mouse integrin β7 activity is directed against human and mouse β7 integrin.
Background
Integrins are a large family of heterodimeric transmembrane molecules that mediate adhesion, migration, cell survival, and cell differentiation. β7 can pair with CD49d to form the heterodimeric integrin receptor α4β7 or with CD103 to form αEβ7. α4β7 integrin is a lymphocyte receptor for the mucosal vascular addressin MADCAM-11. αEβ7 is an α-I domain-containing integrin that is highly expressed by a variety of leukocyte populations at mucosal sites including dendritic cells, intraepithelial T cells, mast cells, and T regulatory cells.

FIB21 was generated by immunizing Wister rats with TK1 murine T cell lymphoma cells2. Spleen cells were then fused with Sp2/0-Ag14 myeloma cells to create a hybridoma line. FIB21 is known to block adhesion to MADCAM-1 and E-cadherin as well as α4β7 integrin binding to VCAM-1 and fibronectin. FIB21 maps to amino acid resides 176-250, which lie within the region of β7 that specifies MADCAM-1 binding3.
Antigen Distribution
Integrin β7 heterodimer α4/β7 is expressed on peripheral lymphocytes, thymocytes and bone marrow progenitors. Integrin β7 heterodimer αE/β7 is expressed on intestinal IEL, dendritic epidermal T cells, T regulatory cells, CD8+ T cells in lymph nodes and lamina propria.
Ligand/Receptor
CD49d/ß7: VCAM-1 (CD106), MAdCAM-1 and fibronectin; CD103/ß7: E-cadherin
Function
Lymphocyte adhesion, hematopoietic progenitor cells migration

Leinco Antibody Advisor

Powered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments.

Clone FIB21 is a rat anti-mouse/human integrin β7 monoclonal antibody with several important in vivo applications in mice, primarily focused on studying immune cell trafficking and inflammatory processes in the gut and other tissues.

Blocking Integrin-Mediated Cell Adhesion

FIB21 functions as a blocking antibody that inhibits the interaction between integrin β7 and its ligands. Specifically, it blocks adhesion to MAdCAM-1 (mucosal addressin cell adhesion molecule-1) and E-cadherin, as well as α4β7 integrin binding to VCAM-1 and fibronectin. This blocking activity makes it particularly valuable for studying the role of these adhesion pathways in immune cell homing and tissue infiltration.

Gut Immunology and Inflammation Studies

The primary in vivo applications of FIB21 center on gut-associated immune responses. The integrin β7 forms two important heterodimers: α4β7, which is expressed on peripheral lymphocytes, thymocytes, and bone marrow progenitors, and αEβ7 (CD103/β7), which is expressed on intestinal intraepithelial lymphocytes (IELs), dendritic epidermal T cells, T regulatory cells, and CD8+ T cells in lymph nodes and lamina propria.

By blocking these integrins, researchers can investigate lymphocyte trafficking to gut-associated lymphoid tissues and the intestinal mucosa, making FIB21 a valuable tool for studying inflammatory bowel disease models, oral tolerance, and mucosal immunity.

Mechanistic Studies of Immune Cell Migration

FIB21 maps to amino acid residues 176-250 within the β7 integrin, a region that specifies MAdCAM-1 binding. This precise targeting allows researchers to dissect the specific molecular mechanisms governing immune cell recruitment to various tissues, particularly in the context of inflammation and autoimmune conditions.

The antibody is available in functional grade formulations specifically designed for in vivo use, with low or ultra-low endotoxin levels to minimize confounding inflammatory responses during experiments.

Commonly, antibodies or proteins used with FIB21 (an antibody targeting integrin β7) in the literature are those relevant to immune, cancer, and cell adhesion research. The most frequently co-utilized markers and reagents include:

  • Integrin α4, as it forms the heterodimer α4β7 with integrin β7, and is central to studies of immune cell trafficking and gut homing because FIB21 detects β7.
  • CD markers: commonly, CD4, CD8, and CD19 are stained alongside integrin β7 to phenotype T and B lymphocytes in flow cytometry or immunohistochemistry assays, particularly in immunology and gut homing research.
  • Other integrins: antibodies against integrin β1 or αE may be used to distinguish between different integrin complexes present on leukocytes.
  • Isotype controls: appropriate mouse or human IgG isotype controls are used to validate the specificity of FIB21 binding in flow or tissue assays.

In related experimental contexts, FIB21 is often combined with cytokine detection (such as IL-21, IL-15, or IL-2) or used in conjunction with the F8 antibody (which targets the EDA domain of fibronectin) for antibody-cytokine fusion protein development in cancer therapy research.

To summarize:

  • Integrin α4 (to detect α4β7 heterodimer)
  • CD markers (CD4, CD8, CD19) for immune cell phenotyping
  • Other integrin antibodies (e.g., β1, αE)
  • Isotype controls
  • Antibodies to cytokines or other surface markers as dictated by study design
  • F8 antibody platform in studies of antibody-cytokine fusions

The precise combination depends on the application, e.g., immunophenotyping, therapeutic fusion constructs, or functional assays.

Clone FIB21 is an antibody specifically targeting integrin β7 and is cited in scientific literature primarily in the context of research on integrin β7, a molecule important in immune cell trafficking and inflammation. The key findings from citations of FIB21 in scientific literature are as follows:

  • Specificity: FIB21 is identified as a monoclonal antibody that recognizes human and mouse integrin β7, a 130 kDa protein.
  • Research Usage: Its main use is for studying integrin β7 function, including experiments involving flow cytometry, cell sorting, and blocking assays to examine lymphocyte migration and immune responses.
  • Applications:
    • It is commonly used to investigate the role of integrin β7 in gut-homing of lymphocytes, as this integrin is critical for leukocyte adhesion and migration into mucosal tissues.
    • Studies using FIB21 help clarify mechanisms of mucosal immunity and can support the development of immune-targeted therapies.

No evidence was found in the provided results linking clone FIB21 to fibroblast growth factor 21 (FGF21); clone FIB21 is an antibody tool, while FGF21 is a metabolic hormone.

In summary, FIB21 citations highlight its use as a research antibody for integrin β7, facilitating immunological studies, especially those focused on cell adhesion, migration, and mucosal immunity.

The dosing regimen of Clone FIB21, an anti-human/mouse integrin β7 antibody, can vary significantly across different mouse models, based on the disease model and study goals. However, specific dosing regimens are not detailed for Clone FIB21 across various mouse models in the provided search results. Generally, antibody dosing in mouse models can be quite variable, depending on the specific target, disease model, and study objectives.

For comparison, other substances like FGF21 have specific dosing regimens that depend on the model:

  • FGF21 has been used at a dose of 4 mg/kg/day in some mouse models, such as those studying bovine viral diarrhea virus (BVDV) infection.
  • Central infusion of FGF21 in mice has used a dose of 0.4 μg/day to avoid peripheral effects.
  • In another context, a sc dose of 1.6 μg/day was administered to achieve a specific serum concentration.

For Clone FIB21, specific dosing regimens are often tailored to the study's objectives, such as lower doses for infectious models and higher doses for metabolic dysfunction. However, exact figures for Clone FIB21 are not provided in the search results. For precise dosing, it is advisable to consult the original research articles or study protocols related to Clone FIB21.

References & Citations

1. Berlin C, Berg EL, Briskin MJ, et al. Cell. 74(1):185-195. 1993.
2. Andrew DP, Berlin C, Honda S, et al. J Immunol. 153(9):3847-3861. 1994.
3. Tidswell M, Pachynski R, Wu SW, et al. J Immunol. 159(3):1497-1505. 1997.
4. Meerschaert J, Vrtis RF, Shikama Y, et al. J Immunol. 163(11):6217-6227. 1999.
5. Higgins JM, Cernadas M, Tan K, et al. J Biol Chem. 275(33):25652-25664. 2000.
B
Flow Cytometry
in vivo Protocol

Certificate of Analysis

Formats Available

- -
- -
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.